ClinicalTrials.gg
RecruitingNCT06782568Avoid-LipoUpdated Feb 13, 2026

Avoidance of Insulin-induced Lipohypertophy in People With Diabetes Using Ultrasound Scanning Within Diabetes Clinics

An interventional study of Ultrasound Scan in Type 1 Diabetes (T1D) and Type 2 Diabetes, Insulin Requiring, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Diabetes Mellitus, Type 1 by Imperial College London — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Imperial College London.

Planned enrollment
Largest of 17
50 · median 23
Started
2026
the only one that year
No phase
16 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies in Diabetes Mellitus, Type 1 by Imperial College London, this one has the largest planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, and was the 22nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 22 studies in Diabetes Mellitus, Type 1 by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Diabetes Mellitus, Type 1 by Imperial College London, or all of them as a file.
02

Study summary

Diabetes is a common long-term health condition globally. Type 1 diabetes requires insulin treatment right from diagnosis. Similarly, many living with type 2 diabetes eventually require insulin injections as the condition progresses. A common but often underappreciated complication associated with insulin use is the formation of fatty tissue at injection sites, known as "Lipos," a shorthand for "Lipohypertrophy." These Lipos can interfere with insulin absorption, leading to an altered insulin action profile. This results in glucose fluctuations increasing the risk of both high and low glucose levels.

In current medical practice, Lipos are assessed through clinical examination, specifically by physically palpating the injection sites. Research indicates that approximately 40% of insulin-treated individuals may have Lipos. However, manual palpation can often overlook these fatty deposits. Ultrasound scanning (USS) presents a more effective method for detecting Lipos. Studies that have employed ultrasound scanning have reported a much higher prevalence, reaching up to 86%.

The primary goal of this study is to ascertain whether the avoidance of ultrasound-identified Lipos can improve glucose regulation. The focus will be on individuals using continuous glucose monitoring who exhibit high glucose fluctuations and less time within their target range. By focusing on this population, the chances of identifying those with Lipos will increase.

Participants will undergo a clinical examination followed by an ultrasound scan. Those found to have Lipos will receive guidance on avoiding those sites and education on insulin injection techniques. Glucose data will be collected periodically over the next 24 weeks. After this period, participants will return for a follow-up ultrasound scan. Additionally, members of the diabetes care team will be trained to conduct the ultrasound scans. Data from this study may also be utilized to develop artificial intelligence algorithms aimed at identifying Lipos in future ultrasound scans.

Read the detailed description

This will be a single-centre, prospective, open-label, non-randomized feasibility study. Participants will be recruited through diabetes clinics at Imperial College Healthcare NHS Trust, London, UK. Written informed consent will be obtained.

Key Inclusion criteria:

  • Any diabetes treated with either multiple daily injection therapy (MDI) or an insulin pump (including automated insulin delivery systems), currently using any form of continuous glucose monitoring (CGM) with use >70% in the last 4 weeks. (Those with type 2 diabetes MDI is defines as more than one insulin injection per day)
  • No anticipated changed to diabetes treatment in the next 6 months.
  • The coefficient of variation (CV) of CGM glucose >36% and Time in the range between 3.9 to 10.0 mmol/l is \<70%
  • Willing to undergo a clinical examination and USS for detection of LH sites

Exclusion criteria:

  • Any other physical disease or people with known severe mental illness that are likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  • Estimated Glomerular Filtration Rate (e-GFR) \< 25
  • Known to have any form of lipodystrophy disorder either primary or secondary to other medical conditions
  • Dercum's disease
  • Women who are pregnant or planning pregnancy
  • The participant has an active major life-threatening illness limiting the participants life-expectancy to \<6 months

The study will be conducted at Imperial College Healthcare NHS Trust. All consented participants will enter a 2-week run-in period where baseline demographic data will be collected and baseline clinical examination and USS will be performed. Continuous glucose monitoring (CGM) data from patients own CGM device will be collected and HbA1c test performed if not done within last 2 weeks. A map of Lipo site will be created and participant advised to avoid these sites for next 24 weeks. CGM data at 4 weeks and 12 weeks post-baseline USS scan will be collected either remotely or in-person. End of study USS, CGM data collection and HbA1c will be conducted at 24 weeks after the baseline USS.

Details of study visits:

Visit 1: Screening \& Enrolment

Potentially eligible participants will attend the diabetes clinic or clinical research facility or will be seen during their scheduled clinic appointments as preferred by participants and availability of clinical space. Following written informed consent, baseline clinical data will be collected from all participants. Information sheets will be provided in advance to potential participants. Following informed consent, those interested in participating will be assessed to determine if they meet the inclusion criteria listed above. A blood sample will be taken for HbA1c \& kidney function if no result is available within the last two weeks. Women of childbearing potential will have a βHCG test to exclude pregnancy.

The following data will be recorded in the CRF:

  1. Informed consent obtained
  2. General Clinical

    1. Date of Birth
    2. Gender
    3. Weight and height
    4. Non-diabetes related co-morbidities
  3. Diabetes clinical

    1. Date of diagnosis
    2. Duration of insulin therapy
    3. Insulin dose (including average total daily insulin, average daily basal insulin, average daily bolus insulin) and other diabetes medications
    4. Complication status
    5. History of severe hypoglycaemia - coma or convulsion (events requiring assistance for recovery in the past 12 months)
    6. History of diabetic ketoacidosis or non-ketotic hyperosmolar coma in the last 12 months
    7. History of participation in structured education or virtual education
    8. Number of boluses per day \& Any evidence of missed boluses
    9. Carbohydrate counting method and use of dynamic insulin doses for meals and corrections
    10. In females, menstrual history and history of high glucose and or glucose variability around periods

CGM data Glucose data from the CGM device will be downloaded and stored in an approved computer. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks.

Visit 2: Baseline Ultrasound Scan (USS)

Participants will have a clinical examination of the insulin injection sites followed by USS of the injection sites. Findings will be documented in the case report forms, and individual maps of injection sites with Lipos created, and participants will be advised to avoid Lipo sites for the next 24 weeks. Insulin needle lengths (4 mm needles advised if on longer needles) and injection techniques will also be paid attention to.

If no significant lipohypertophy (LH) is detected by USS, participants will take no further part in the study

Visit 3: Four-week follow visit

This visit could be done as a remote visit. Glucose data from the CGM device will be downloaded and stored. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks.

Visit 4: 12-week follow visit

This visit could be done as a remote visit. Glucose data from the CGM device will be downloaded and stored. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks.

Visit 5: End of Study Visit (24-weeks)

All participants will have blood sample taken for HbA1c. Glucose data from the CGM device will be downloaded and stored. Summary CGM statistics using usual clinical software (Carelink, Libreview, Dexcom Clarity) will also be recorded for last 4 weeks. Participants will have a clinical examination of the insulin injection sites followed by USS of the injection sites. Information about current insulin doses will also be collected. This will be the end of study.

03

Conditions studied

  • Type 1 Diabetes (T1D)
  • Type 2 Diabetes, Insulin Requiring

Keywords

  • Lipohypertophy
  • Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years and above
  • Any type of diabetes of at least 1-year duration managed with multiple daily injections (MDI [ie separate rapid-acting and basal insulin injections]) or insulin pump therapy (CSII)
  • Currently using any form of continuous glucose monitoring (CGM) with use >70% in the last 4 weeks
  • No anticipated changes to diabetes treatment in the next 6 months such as introduction of novel agents like GLP-1, SGLT2 or introduction (Tupe 2 diabetes) or AID (Type 1 diabetes)
  • Coefficient of variation (CV) of CGM glucose >36% and Time in the range between 3.9 to 10.0 mmol/l is \<70%
  • The participant is willing and able to implement the study requirements and undergo two ultrasound scans of the insulin injection sites
  • Participants is able understand English sufficiently for safe study conduct

Exclusion criteria

Exclusion Criteria:

  • Any other physical disease or people with known severe mental illness that are likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
  • Known to have any form of lipodystrophy disorder either primary or secondary to other medical conditions
  • Dercum's disease
  • Women who are pregnant or planning pregnancy
  • The participant has an active major life-threatening illness limiting the participants life-expectancy to \<6 months
  • Estimated (e-GFR) \< 25
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ultrasound scanning of insulin injection sites

    Participants will undergo clinical examination followed by ultrasound scanning (USS) of the injection sites at baseline. If there is no significant lipohypertophy (LH) detected by USS, participants will take no further part in the study. If there is LH detected on USS, an individualised map of LH sites and clear sites will be drawn, and the participant will be asked to avoid LH sites for the next 6 months. Follow up remote/virtual/F2F visits will be conducted at 1 and 3 months. The final visit at 6 months will consist of a repeat clinical examination followed by a repeat USS.

    Diagnostic Test: Ultrasound Scan

Interventions

  • Diagnostic testUltrasound Scan

    Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.

06

What researchers measure

Primary outcomes

  1. Time in Range (3.9 to 10.0 mmol/l)

    Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180 mg/dl) based on sensor glucose levels for the last 4 weeks of the 24 week study period

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. HbA1c

    Change in HbA1c from baseline

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Mean glucose

    Mean glucose levels at 24 weeks

    Time frame: From enrollment to the end of treatment at 24 weeks

  3. Time above range (Level 1)

    Time spent above target glucose (10.0 mmol/l) (180 mg/dl) (Level 1 hyperglycaemia)

    Time frame: From enrollment to the end of treatment at 24 weeks

  4. Time above range (Level 2)

    Time spent above target glucose (13.9 mmol/l) (250 mg/dl) (Level 2 hyperglycaemia)

    Time frame: From enrollment to the end of treatment at 24 weeks

  5. Time below range (Level 1)

    Time spent below target glucose (\<3.9mmol/l) (\<70mg/dl) (Level 1 hypoglycaemia)

    Time frame: From enrollment to the end of treatment at 24 weeks

  6. Time below range (Level 2)

    Time spent below target glucose (\<3.0mmol/l) (\<54mg/dl) (Level 2 hypoglycaemia)

    Time frame: From enrollment to the end of treatment at 24 weeks

  7. Insulin doses

    Average total daily insulin dose, basal and bolus dose

    Time frame: From enrollment to the end of treatment at 24 weeks

  8. Severe Hypoglycaemia

    Frequency of severe hypoglycaemic episodes as defined by the American Diabetes Association

    Time frame: From enrollment to the end of treatment at 24 weeks

  9. Resolution of Lipohypertrophy (LH)

    Resolution rate of Lipohypertrophy (% of participants affected and number of distinct LH sites per participant)

    Time frame: From enrollment to the end of treatment at 24 weeks

  10. Time in Range (3.9 to 10.0 mmol/l)

    Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180 mg/dl) based on sensor glucose levels

    Time frame: From enrollment to the end of treatment at 12 weeks

  11. Time in Range (3.9 to 10.0 mmol/l)

    Time spent in the target glucose range between 3.9 to 10.0 mmol/l (70 to 180 mg/dl) based on sensor glucose levels

    Time frame: From enrollment to the end of treatment at 4 weeks

  12. Glucose variability

    Coefficient of Variation of glucose levels at 24 weeks

    Time frame: From enrollment to the end of treatment at 24 weeks

Other outcomes

  1. Adverse Events

    Adverse events will be tabulated and reported

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mader JK, Fornengo R, Hassoun A, Heinemann L, Kulzer B, Monica M, Nguyen T, Sieber J, Renard E, Reznik Y, Rys P, Stozek-Tutro A, Wilmot EG. Relationship Between Lipohypertrophy, Glycemic Control, and Insulin Dosing: A Systematic Meta-Analysis. Diabetes Technol Ther. 2024 May;26(5):351-362. doi: 10.1089/dia.2023.0491. Epub 2024 Feb 12. PubMed 38215209 ↗

Individual participant data

Plan to share: No — This is a single-arm feasibility study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 11 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 20, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06782568
Collaborators
Imperial College Healthcare NHS Trust
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Lalantha Leelarathna, PhD FRCP (UK)
Contact
e.leelarathna@imperial.ac.uk
+447984477771
Lalantha Leelarathna, PhD FRCP
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion